Kaskela Law Investigates FONAR Buyout for Potential Undervaluation
Event summary
- Kaskela Law is investigating the fairness of FONAR Corp.'s proposed $19.00 per share buyout, announced on December 29, 2025.
- The investigation focuses on whether the buyout price undervalues FONAR's shares and whether company officers/directors breached fiduciary duties.
- FONAR shareholders will be cashed out, and the company's shares will no longer be publicly traded post-transaction.
- Kaskela Law encourages FONAR investors to contact them for information on legal rights and options.
The big picture
Kaskela Law's investigation into FONAR's buyout highlights the growing scrutiny over private equity deals in the healthcare sector. The probe underscores broader concerns about fair valuation and fiduciary duties in corporate transactions, particularly as more companies face pressure to justify buyout terms to shareholders. The outcome could influence future M&A activity and legal strategies in similar cases.
What we're watching
- Valuation Dispute
- How the $19.00 per share buyout price will be scrutinized for potential undervaluation of FONAR's shares.
- Legal Precedent
- Whether this investigation sets a precedent for similar buyout challenges in the healthcare sector.
- Shareholder Activism
- The pace at which shareholder activism increases in response to perceived undervaluation in private equity deals.
Related topics